Aether Industries Limited — Q3 FY26 earnings call

Call held 3 Feb 2026

Management summary

Aether Industri. reported strong Q3 FY26 results with significant YoY growth in revenue, EBITDA, and PAT, driven by robust demand and strategic expansions. The company completed construction of Site 3++ and Site 5, with commercial production imminent. While working capital increased due to inventory buildup for new plants, management remains confident in its long-term strategic partnerships and R&D-led growth in specialty chemicals.

Highlights

  • Consolidated Revenue from operations for Q3 FY26 increased 44% YoY to INR3,171 million.

  • EBITDA for Q3 FY26 grew 75% YoY to INR1,083 million, with EBITDA margin expanding to 34%.

  • PAT for Q3 FY26 increased 49% YoY to INR645 million, achieving a PAT margin of 20%.

  • Construction and installation of Site 3++ and the first two production blocks of Site 5 are completed, with commercial production commencing shortly.

  • Large-scale manufacturing business vertical saw volume growth of over 10% QoQ and over 25% YoY.

Concerns

  • Net working capital cycle increased to 160 days from 149 days (Sep 30, 2025) mainly due to inventory buildup for the upcoming start of Site 3++ and Site 5.

  • A one-time FLOP claim of INR15 crores was classified in 'other revenue', temporarily impacting reported margins, which are otherwise guided to be conservatively 29-30%.

Key financials

2 periods

Headline

  • Consolidated Revenue
    3,171 Mn
    YoY +44%
  • Consolidated EBITDA
    1,083 Mn
    YoY +75%
  • EBITDA Margin
    34%
  • Consolidated PAT
    645 Mn
    YoY +49%
  • PAT Margin
    20%

9M

  • Consolidated Revenue
    8,534 Mn
    YoY +43%
  • Consolidated EBITDA
    2,716 Mn
    YoY +75%
  • Consolidated PAT
    1,655 Mn
    YoY +53%
  • PAT Margin
    19%

What they filed

Q1 FY27: revenue up 27.2%, net profit up 34.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue199 220 240 257 280 +41%319 +45%305 +27%327 +27%
EBITDA54 65 80 81 88 +63%112 +72%83 +4%103 +27%
Net profit35 43 50 47 54 +54%64 +49%54 +8%63 +34%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex ₹450 Cr
    • CWIP for Site 3++ and Site 5 (Panoli) ₹500 Cr
    • Capitalization of Panoli (Site 5, 2 blocks) ₹200 Cr
    • Capitalization of Site 3++ ₹250 Cr
    In the 9 months, we have approximately done the CWIP, which stands for Site 3++ and Panoli, the Site 5, approximately INR500 crores. This year, it will be -- both the sites will -- Phase 2 of -- sorry, 2 blocks of the Phase 1 will be ready for Panoli, which will be capitalized and there will be still approximately INR200 crores in the CWIP and Site 3++ also will be capitalized, which will be approximately INR250 crores or INR260 crores odd.
  • Liquidity Liquidity disclosed Net working capital cycle increased to 160 days due to inventory buildup for Site 3++ and Site 5, which are expected to begin from March '26.
    The net working capital cycle remains at 160 days as against 149 days as on September 30, '25, mainly because of inventory buildup for the start of Site 3++ and Site 5, which are expected to begin from March '26.

Guidance & targets

Business Mix

  • Revenue contribution from CRAMS and CEM Business Mix · future (2-3 years) · High confidence 70%
    So what we are targeting is basically 70% of our revenue coming from CRAMS and CEM and 30% coming from large scale manufacturing.

    — Kushal Doshi

  • Revenue contribution from large scale manufacturing Business Mix · future (2-3 years) · High confidence 30%

    — Kushal Doshi

Margin

  • Sustainable EBITDA margin Margin · future · High confidence 29-30%
    No, it will -- we would like to still be conservative and we'll always be around -- would like to be around 29% to 30% is not more than that.

    — Faiz Nagariya

Capacity Utilization

  • Site 3++ capacity utilization Capacity Utilization · FY27 · High confidence 45-50%
    So see, Site 3++, which starts from the month of March -- the next year, it will be the first year. We anticipate it to be approximately around 45% to 50% capacity utilization.

    — Faiz Nagariya

  • Site 5 (2 blocks) capacity utilization Capacity Utilization · FY27 · High confidence 35-40%
    And Site 5 will be just 2 blocks we are starting, and we expect that to be around 35% to 40% capacity utilization in the next year.

    — Faiz Nagariya

Product Commercialization

  • Converge polyol capacity Product Commercialization · approx 3 years · Medium confidence 2 KTA (2,000 tonnes)
    Three years down the line, we would be doing 2 KTA approximately. That's our target -- initial target.

    — Rohan Desai

  • Milliken-sized molecules converting to significant contracts Product Commercialization · 1-3 years · Medium confidence 3-4 molecules
    In the next -- between 1 to 3 years, all of these should be panning out into significant contracts.

    — Aman Desai

Sales Target

  • Otsuka Chemical sales Sales Target · FY26 · High confidence INR35-40 crores
    Our contract with Otsuka Chemical is on track and we are expected to achieve a target of INR35 crores to INR40 crores of sales in financial year 2026.

    — Rohan Desai

What to watch in Q4 FY26

Site 3++ Commercial Production

shortly (March '26)
Current Construction and trials completed
Target Commercial production commenced

Why it matters

Crucial for new capacity utilization and revenue generation from expansion projects.

I'm delighted to inform you that the construction and installation of Site 3++ and the first 2 production blocks of Site 5 has been completed and water plus and solvent trials have been commenced. Commercial production from these sites will comment shortly.

Risks & concerns

  • Volatile Macro Environment

    medium

    Global environment continues to remain volatile, but customer inquiries are increasing.

    Management acknowledged

  • China Competition and Pricing Pressure

    medium

    LSM business faces aggressive payment terms from China. Lithium-ion battery chemical project put on hold due to aggressive pricing from China. Management will monitor China's pricing post-holidays.

    Both acknowledged

  • Increased Working Capital Cycle

    low

    Working capital cycle increased to 160 days due to inventory buildup for new plants (Site 3++ and Site 5) starting commercial production in March '26, considered temporary.

    Management acknowledged

Q&A highlights

7 direct
Talent Retention and Culture during Scale-up Direct
We lead from the top. We are family and our promoter family is a mix of techno-commercial excellence. Our Chairman and Managing Director, Ashwin Desai, our father, is a chemical engineer. I am a chemical engineer by bachelor's, and a PhD in organic chemistry, and so we lead from the top, especially when there are problems. We are very, very involved.

Highlights management's proactive approach to talent management and the company's culture of leadership involvement and acceptance of R&D outcomes.

Asked by Sajal Kapoor

CEM Strategy and CRAMS to CEM Conversion Timeline Direct
The answer is both. We work extremely hard in curating and establishing these relationships, our relationships with these innovators is at the topmost levels in the techno-commercial domains. And these relationships are led directly by Rohan or myself or Norbert or Jim or Ray Roach, which are our business development leaders. ... It really depends. We have examples where this has happened in 6 months. And then we have examples where it has taken 6 years to convert such customers into the context of exclusive manufacturing business. It simply depends upon their pipeline and the timeline of these pipelines. So if you look at a pharma molecule, the pipeline to take something from Phase I to commercial is 7, 8 years. If you look at oil and gas, the timeline is 1 year, right? And so everything in between. So it really depends. But on average, you should consider, I think, between 1 to 2 years.

Clarifies the dual strategy for CEM growth and provides realistic timelines for converting CRAMS projects to exclusive manufacturing, which is crucial for revenue visibility.

Asked by Parikshit Gujarati

Outsourcing Preference and Protection from Pricing Pressure in CEM Direct
I think as we said as I said in my commentary that in the West, it's increasingly impossible to manufacture any more or even scale up anymore. And so back integration for these customers is simply out of the question in Europe and America because it's just not economical for them to do so. The pricing has increased significantly across all fronts in the West, where, in our case, in India, the pricing is remaining consistent, slightly increasing. And so there is no way the process and product economics of the rest can compete with Indian economics.

Explains Aether's competitive advantage in the CEM segment, particularly against Western manufacturers, and how transparent costing protects against pricing pressure.

Asked by Darshan Garg

Working Capital Cycle and Inventory Buildup Direct
Yes. So we are still able to manage the working capital, and it was 149, 150 days on 31st March, which is sorry, on 30th September, which is approximately 160 days only just because we have procured inventories, raw materials for the Site 3++ coming up and also Site 5. So we have built up some inventories because the production starts from March onwards. Otherwise, everything is in control, which was there in September 30.

Provides a clear explanation for the temporary increase in working capital, linking it directly to the upcoming commercialization of new production sites.

Asked by Kumar Saumya

Sustainable EBITDA Margin Guidance Direct
No, it will -- we would like to still be conservative and we'll always be around -- would like to be around 29% to 30% is not more than that. I told you, there is a certain onetime this FLOP claim has come up. That has also increased the margins a bit because it's put up in the other revenues. Otherwise, we'll be around 29%, 30-ish percent.

Clarifies the company's long-term margin expectations, distinguishing between one-time impacts and sustainable levels, which is key for valuation.

Asked by Kumar Saumya

Lithium Battery Chemicals Business Status Partial
Yes, that was one -- that was for electrolyte additives, where we had developed these for the first time in India, and we had tied up with a global partner for that. After this time last year, the pricing in China became extremely aggressive and tanked to almost half of what it was. And so at that time, it was not economically viable for us. And so we had put the entire project and the entire field on hold, on pause. These stand developed, these stand scaled up, these stand ready to be launched into manufacturing.

Provides an update on a previously announced project, explaining the reasons for its current 'on hold' status due to market pricing, indicating a pragmatic approach to project execution.

Asked by Bhavika Jain

Fungibility of Manufacturing Plants Direct
Yes. Thank you. We have the focus from day 1 in the manufacturing has been to build fungible plants and multipurpose plants across individual core competencies, our so-called 8x8 metrics. And so when we build plants, then we build them so that they are multipurpose and fungible across these core competencies, and we focus on these core competencies.

Highlights a core strategic advantage of Aether's manufacturing setup, which provides flexibility and reduces risk in case of contract changes or market shifts.

Asked by Chintan Shah

Rationale for Clients Choosing Aether as Sole Supplier Direct
Multiple answers to that question, but it's a strategic partnership that is enabled. They are also very keen to have only single suppliers or because of the intellectual property protection, the confidentiality protection as well. They are innovators who want to protect their technology and not have it be in the hands of multiple people. Also, it's the confidence that we provide these customers and innovators and the relationship that we have and the executional innovation capabilities that we have, which lets them gives them enough confidence that having only partners will suffice.

Explains the deep strategic reasons behind Aether's sole supplier relationships, emphasizing IP protection, trust, and execution capabilities, which are critical for long-term CRAMS/CEM contracts.

Asked by Naushad Chaudhary

3 min read 6 chapters

Detailed narrative

Q3 FY26 Financial Performance Overview

Aether Industri. reported strong financial performance for Q3 FY26, with consolidated revenue from operations increasing by 44% YoY to INR3,171 million. EBITDA saw a significant 75% YoY growth, reaching INR1,083 million, and the EBITDA margin expanded to 34% from 28% in Q3 FY25. Net profit after tax (PAT) also grew by 49% YoY to INR645 million, resulting in a PAT margin of 20% for the quarter. For the nine months ended December 31, 2025, revenue increased 43% to INR8,534 million, EBITDA grew 75% to INR2,716 million, and PAT rose 53% to INR1,655 million.

Capacity Expansion and Commercialization Progress

The company announced the completion of construction and installation for Site 3++ and the first two production blocks of Site 5. Water and solvent trials have commenced, with commercial production from these sites expected to begin shortly, specifically from March 2026. The total CWIP for Site 3++ and Site 5 amounted to approximately INR500 crores in the first nine months of FY26. For FY27, Site 3++ is targeted for 45-50% capacity utilization, while the two blocks of Site 5 are expected to achieve 35-40% utilization.

Business Vertical Performance and Outlook

In Q3 FY26, sales composition included 43% from contracts plus exclusive manufacturing, 41% from large-scale manufacturing, and 8% from contract research and manufacturing services. Large-scale manufacturing demonstrated robust volume growth of over 10% QoQ and 25% YoY. Sales from Site 4 increased 20% QoQ to INR60 crores. The company expects the share of Oil and Gas (22%) and Material Science (18%) sectors to scale up by year-end, with a long-term target of 70% revenue from CRAMS/CEM and 30% from large-scale manufacturing.

R&D and New Client Initiatives

Aether is undertaking significant R&D expansion, including adding 20 fume hoods and engineering labs in the short term, and 15 additional labs with 150 fume hoods and advanced analytical equipment like NMR in the long term. This expansion focuses on chemical engineering for non-pharma, non-agro, oil and gas, and material science sectors. The company has secured a CEM exclusive contract with a European chemical company in the material science sector, which will utilize a modified production line in Site 3. Validation batches for electronic chemicals for the semiconductor industry, targeting Japan, South Korea, and Taiwan, have already been dispatched.

Working Capital and Margin Management

The net working capital cycle increased to 160 days in Q3 FY26 from 149 days as of September 30, 2025. This increase is primarily attributed to inventory buildup in preparation for the commercial launch of Site 3++ and Site 5 in March 2026. Management maintains a conservative sustainable EBITDA margin guidance of 29-30%, noting that the reported 34% margin in Q3 FY26 was partially influenced by a one-time FLOP claim of INR15 crores.

Strategic Partnerships and Outsourcing Advantages

Management emphasized its strategy of building long-term strategic partnerships, particularly in the CEM segment, where it aims to be a 'go-to partner' and 'one-stop solution' for innovators. The company highlighted its competitive edge due to favorable Indian economics compared to the West, transparent costing models, and a commitment to long-term relationships (20 years, 10 projects in pipeline). Aether's focus on IP protection, trust, and executional innovation, coupled with redundant and fungible manufacturing sites, allows it to be a sole supplier for key clients like Baker Hughes.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls